Overview
Anemia is a common complication of chronic kidney disease (CKD) and is associated with significant morbidity and adverse clinical outcomes 1.Diagnosis
No diagnostic criteria or recommended tests are detailed in the provided abstracts.Management
Hypoxia-inducible factor-prolyl hydroxylase inhibitors (HIF-PHIs) are a new class of agents for treating anemia in CKD 1.
Established and emerging therapies for anemia and iron deficiency in CKD have been assessed 1.Special Populations
No information on special populations is provided in the abstracts.Key Recommendations
KDIGO published guidelines for the diagnosis and management of anemia in CKD in 2012 1.
New data on established and emerging therapies for anemia and iron deficiency in CKD have become available since the 2012 guidelines 1.
Hypoxia-inducible factor-prolyl hydroxylase inhibitors (HIF-PHIs) represent a new class of agents for anemia management in CKD 1.References
1 Ku E, Del Vecchio L, Eckardt KU, Haase VH, Johansen KL, Nangaku M et al.. Novel anemia therapies in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney international 2023. link